logo
Share SHARE
FONT-SIZE Plus   Neg

Supervalu: Sam Duncan Assumes Executive Role Effective Immediately - Quick Facts

Supervalu Inc. (SVU) announced Monday that Sam Duncan will become president and chief executive officer, effective immediately. He succeeds Wayne Sales, who has served as the Company's president and chief executive officer since July 2012.

Last month, Supervalu announced an agreement with AB Acquisition LLC to sell five of its retail banners as well as enter into an agreement with Symphony Investors LLC to conduct a tender offer for up to 30 percent of Supervalu's outstanding common stock at a purchase price of $4.00 per share in cash. Both AB Acquisition LLC and Symphony Investors LLC are Cerberus Capital Management-led entities.

Previously, Supervalu had announced that Duncan would assume the role of president and chief executive officer upon closing of the transaction.

Supervalu said that Wayne Sales oversaw its review of strategic alternatives, and as executive chairman, will continue to have oversight over the completion of the transaction. At the closing of the transaction, Robert Miller, current president and CEO of Albertsons LLC, will become Supervalu's non-executive chairman.

Duncan, 61, most recently served from 2005-2011 as chairman, CEO and president of OfficeMax. Prior to joining OfficeMax, Duncan served as president and CEO of ShopKo Stores from 2002-2005. He has over 40 years of experience in the retail industry, including nearly 30 years with Albertsons and Kroger in positions of increasing responsibility.

The company also reaffirmed that the closing of the previously announced sale and tender offer process is expected to occur the week of March 18th.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Credit Suisse Group AG gained around 8 percent in the morning trading in Zurich after the Swiss banking giant raised its group cost savings target, and also confirmed its medium-term 2018 pre-tax income target. It is almost the end of the year. With the exception of a few, many of the biotech stocks, like the following, on which investors had bet big this year have served up only heartbreak. Now, let's take a look at some of the pending clinical trial catalysts of this month, which will make it a December to remember. Fast food major McDonald's is investing in $12,000 espresso machines for all of its U.S. restaurants, with a view to challenge Starbucks and Dunkin' Donuts in the coffee business, Bloomberg reported. Aiming to attract more customers, the company plans to reintroduce its coffee shop McCafe in 2017..
comments powered by Disqus
Follow RTT